ABIONYX Pharma SA (LON:0RAG)

ABIONYX Pharma Statistics

Total Valuation

ABIONYX Pharma has a market cap or net worth of GBP 110.63 million. The enterprise value is 111.28 million.

Market Cap	110.63M
Enterprise Value	111.28M

Important Dates

The next estimated earnings date is Thursday, March 12, 2026.

Earnings Date	Mar 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	35.28M
Shares Outstanding	n/a
Shares Change (YoY)	+11.34%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	32.06%
Owned by Institutions (%)	4.30%
Float	21.18M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	29.83
PB Ratio	23.46
P/TBV Ratio	2,435.21
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-28.23
EV / Sales	29.53
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-35.44

Financial Position

The company has a current ratio of 1.40, with a Debt / Equity ratio of 0.75.

Current Ratio	1.40
Quick Ratio	1.30
Debt / Equity	0.75
Debt / EBITDA	n/a
Debt / FCF	-1.12
Interest Coverage	-65.79

Financial Efficiency

Return on equity (ROE) is -61.53% and return on invested capital (ROIC) is -74.81%.

Return on Equity (ROE)	-61.53%
Return on Assets (ROA)	-20.47%
Return on Invested Capital (ROIC)	-74.81%
Return on Capital Employed (ROCE)	-50.87%
Weighted Average Cost of Capital (WACC)	8.84%
Revenue Per Employee	72,710
Profits Per Employee	-77,299
Employee Count	51
Asset Turnover	0.30
Inventory Turnover	17.39

Taxes

In the past 12 months, ABIONYX Pharma has paid 6,858 in taxes.

Income Tax	6,858
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +184.80% in the last 52 weeks. The beta is 0.88, so ABIONYX Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.88
52-Week Price Change	+184.80%
50-Day Moving Average	3.73
200-Day Moving Average	2.77
Relative Strength Index (RSI)	41.17
Average Volume (20 Days)	482

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ABIONYX Pharma had revenue of GBP 3.71 million and -3.94 million in losses. Loss per share was -0.11.

Revenue	3.71M
Gross Profit	659,182
Operating Income	-4.00M
Pretax Income	-3.94M
Net Income	-3.94M
EBITDA	-3.91M
EBIT	-4.00M
Loss Per Share	-0.11

Balance Sheet

The company has 2.89 million in cash and 3.53 million in debt, with a net cash position of -636,895.

Cash & Cash Equivalents	2.89M
Total Debt	3.53M
Net Cash	-636,895
Net Cash Per Share	n/a
Equity (Book Value)	4.72M
Book Value Per Share	0.13
Working Capital	1.34M

Cash Flow

In the last 12 months, operating cash flow was -2.96 million and capital expenditures -177,439, giving a free cash flow of -3.14 million.

Operating Cash Flow	-2.96M
Capital Expenditures	-177,439
Free Cash Flow	-3.14M
FCF Per Share	n/a

Margins

Gross margin is 17.78%, with operating and profit margins of -107.98% and -106.31%.

Gross Margin	17.78%
Operating Margin	-107.98%
Pretax Margin	-106.13%
Profit Margin	-106.31%
EBITDA Margin	-105.32%
EBIT Margin	-107.98%
FCF Margin	n/a

Dividends & Yields

ABIONYX Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.34%
Shareholder Yield	-11.34%
Earnings Yield	-3.56%
FCF Yield	-2.84%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ABIONYX Pharma has an Altman Z-Score of 2.5 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.5
Piotroski F-Score	1